title: Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial.
abstract: BACKGROUND
  Although recent studies have documented the benefit of adjunctive antidepressant medication for the short-term treatment of certain patients with operationally defined syndromes of postpsychotic depression, the value of maintenance adjunctive antidepressant treatment in this circumstance has not been properly established.
  
  
  METHODS
  This study examined 24 schizophrenic or schizoaffective patients with postpsychotic depression or negative symptoms. These patients had all been benefited over the short term by the addition of adjunctive imipramine hydrochloride to their ongoing fluphenazine decanoate/benztropine mesylate regimens, and this adjunctive treatment had been successfully continued for 6 months. In a randomized double-blind protocol, treatment with adjunctive imipramine hydrochloride (mean, 233 +/- 72 mg/d) was then either maintained or tapered to placebo for an ensuing 1-year trial, while treatment with fluphenazine and benztropine continued.
  
  
  RESULTS
  Significantly more patients who received placebo substitution relapsed into depression (P < .001). Patients who received placebo substitution were also more likely to experience relapses into psychosis (P < .02).
  
  
  CONCLUSIONS
  These results support the clinical value of maintenance adjunctive imipramine therapy among initially responsive patients with postpsychotic depressions.
authors.affiliation: Hillside Hospital Division, Long Island Jewish Medical Center, Albert Einstein College of Medicine, Glen Oaks, NY.
authors.forename: S G
authors.initials: SG
authors.lastname: Siris
authors.forename: P C
authors.initials: PC
authors.lastname: Bermanzohn
authors.forename: S E
authors.initials: SE
authors.lastname: Mason
authors.forename: M A
authors.initials: MA
authors.lastname: Shuwall
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001590:Benztropine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000209:etiology / Q000517:prevention & control*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005476:Fluphenazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D012008:Recurrence; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D010919:Placebos; D001590:Benztropine; C011825:fluphenazine depot; D007099:Imipramine; D005476:Fluphenazine